HK1223547A1 - 癌症治疗方法 - Google Patents

癌症治疗方法 Download PDF

Info

Publication number
HK1223547A1
HK1223547A1 HK16111783.0A HK16111783A HK1223547A1 HK 1223547 A1 HK1223547 A1 HK 1223547A1 HK 16111783 A HK16111783 A HK 16111783A HK 1223547 A1 HK1223547 A1 HK 1223547A1
Authority
HK
Hong Kong
Prior art keywords
entinostat
administration
administered
patient
fed
Prior art date
Application number
HK16111783.0A
Other languages
English (en)
Chinese (zh)
Inventor
．古德諾
R.古德诺
．奧登特里科
P.奥登特里科
Original Assignee
欣达克斯制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 欣达克斯制药公司 filed Critical 欣达克斯制药公司
Publication of HK1223547A1 publication Critical patent/HK1223547A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16111783.0A 2013-05-03 2014-05-02 癌症治疗方法 HK1223547A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1223547A1 true HK1223547A1 (zh) 2017-08-04

Family

ID=51843995

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111783.0A HK1223547A1 (zh) 2013-05-03 2014-05-02 癌症治疗方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (enExample)
JP (2) JP2016522188A (enExample)
KR (1) KR102337598B1 (enExample)
CN (1) CN105492007A (enExample)
HK (1) HK1223547A1 (enExample)
WO (1) WO2014179738A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028287A2 (en) * 2015-06-29 2018-09-04 Syndax Pharmaceuticals, Inc. COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
EP2046299A1 (en) * 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
BRPI0909818A2 (pt) * 2008-03-07 2015-10-06 Pfizer métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
JP6195384B2 (ja) * 2011-09-02 2017-09-13 シンダックス ファーマシューティカルズ，インク． 乳癌の処置方法

Also Published As

Publication number Publication date
CN105492007A (zh) 2016-04-13
EP2991650A4 (en) 2017-01-25
JP6860949B2 (ja) 2021-04-21
KR20160003182A (ko) 2016-01-08
EP2991650A1 (en) 2016-03-09
JP2016522188A (ja) 2016-07-28
WO2014179738A1 (en) 2014-11-06
JP2019112416A (ja) 2019-07-11
KR102337598B1 (ko) 2021-12-10

Similar Documents

Publication Publication Date Title
RU2745678C2 (ru) Способы лечения рака
KR101689946B1 (ko) 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
HK1254859A1 (zh) 治疗乳腺癌的方法
JP6860949B2 (ja) 癌の処置方法
KR102439911B1 (ko) 제약학적 복합제제
KR20180022926A (ko) 암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
CN108139403B (zh) 用于组合疗法的患者的选择
KR20180095586A (ko) 난소암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
KR20210105388A (ko) 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
US20130150386A1 (en) Methods for the treatment of lung cancer
CA3140146A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
TW202434251A (zh) 治療癌症之療法
CN121015865A (zh) 用于组合疗法的患者的选择
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
HK1257617A1 (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
HK1257617B (en) Use of a composition for inhibiting tie2 kinase in the manufacture of a medicament for treating cancer